Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 3 2Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Adenocarcinoma 3Lung Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Neoplasm Metastasis 1Metastatic Gastric Adenocarcinoma 1Liver Neoplasms 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Gastroesophageal Junction Adenocarcinoma 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Fluorouracil 131Leucovorin 127Oxaliplatin 93Bevacizumab 86Irinotecan 74Capecitabine 63Cetuximab 47Folfox protocol 32Panitumumab 18regorafenib 16trifluridine tipiracil drug combination 15Drug Therapy 14Chemotherapy, Adjuvant 13IFL protocol 10Floxuridine 10Radiotherapy 9Tegafur 7Neoadjuvant Therapy 7Levoleucovorin 7Laparoscopy 7Aspirin 7pembrolizumab 6atezolizumab 6Trifluridine 6Celecoxib 6XELOX 5Mitomycin 5Colonoscopy 5tipiracil 4sintilimab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Colorectal Neoplasms × Ramucirumab × Clear all
NCT03520946 2024-08-09

RAMTAS

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 3 Completed
430 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT01183780 2019-09-25

A Study in Second Line Metastatic Colorectal Cancer

Eli Lilly and Company

Phase 3 Completed
1,072 enrolled 17 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡